ClinicalTrials.gg
RecruitingNCT06469944Updated Nov 13, 2026

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

A Phase 1/2 interventional study of Pembrolizumab and Sacituzumab Tirumotecan (sac-TMT) in Gastroesophageal Junction, Gastroesophageal Adenocarcinoma and Esophageal Neoplasms, sponsored by Merck Sharp & Dohme LLC. Recruiting at 50 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.
Updated Nov 13, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Esophageal Neoplasms by Merck & Co., Inc — 3 open to participants now, 3 under way, none of them phase 3. Esophageal Neoplasms · Merck & Co., Inc.

Planned enrollment
6th of 13
160 · median 123
Started
2024
with 1 other
Phase 1/2
4 of 13
3 open now
Registered
13th of 13
by date

Among the 13 studies in Esophageal Neoplasms by Merck & Co., Inc, this one is the 6th largest by planned enrollment, is one of 2 that started in 2024, is one of 4 in phase 1/2, and was the 13th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

3 of the 13 studies in Esophageal Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Esophageal Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma.

This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study.

Read the detailed description

The master protocol is MK-3475-U06.

03

Conditions studied

  • Gastroesophageal Junction
  • Gastroesophageal Adenocarcinoma
  • Esophageal Neoplasms
  • Esophageal Cancer

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has and/or cytologically confirmed diagnosis of previously untreated locally advanced unresectable or (1L) gastroesophageal adenocarcinoma
  • Is not expected to require tumor resection during the treatment course
  • Tumor tissue must be confirmed as negative for human epidermal growth factor receptor 2 () expression as classified by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines
  • Core/excisional of a tumor lesion not previously irradiated has been provided
  • Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline
  • Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy are eligible
  • Has adequate organ function
  • Has per Version 1.1 (RECIST 1.1) as determined by the local site investigator/radiology assessment and verified by blinded independent central review (BICR)
  • Has (ECOG) performance status of 0 or 1 within 3 days prior to the first dose of study intervention
  • Has a of at least 6 months
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation/randomization
  • Participants with history of Virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • (HIV)-infected participants must have well controlled HIV on antiretroviral therapy

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has squamous cell or undifferentiated gastroesophageal cancer.
  • Has had previous therapy for locally advanced unresectable or gastric/gastroesophageal junction (GEJ)/esophageal adenocarcinoma
  • Has experienced weight loss >20% over 3 months before the first dose of study intervention
  • Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has Grade ≥2 peripheral neuropathy
  • Has active inflammatory bowel disease requiring medication or previous history of inflammatory bowel disease
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within 6 months preceding study intervention
  • Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment
  • Has history of (HIV) infection with Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has received prior treatment with a trophoblast antigen 2 (TROP2)-targeted or anti-human epidermal growth factor receptor 3 (HER3) targeted agents
  • Has received prior treatment with a topoisomerase I inhibitor-based antibody-drug conjugate (ADC) and/or a topoisomerase I inhibitor-based chemotherapy
  • Has received prior systemic anticancer therapy within 4 weeks before the first dose of study intervention
  • Has received prior therapy with an anti-Programmed Cell Death Protein 1 (), anti-Programmed Cell Death-Ligand 1 (PD-L1), anti-Programmed Cell Death-Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (TCR)
  • Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation related toxicities, requiring
  • Has received a live or within 30 days before the first dose of study intervention
  • Has received a strong inducer/inhibitor of that cannot be discontinued
  • Has received an agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
  • Has known additional that is progressing or has required active treatment within the past 3 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has Severe (≥Grade 3) to pembrolizumab, sacituzumab tirumotecan, patritumab deruxtecan, or other biologic therapy, chemotherapy (ie, oxaliplatin, fluorouracil, capecitabine), leucovorin, levoleucovorin, or any of their
  • Has active disease that has required systemic treatment in the past 2 years
  • Has history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at Screening
  • Has an active infection requiring systemic therapy
  • Has concurrent active (defined as Hepatitis B surface antigen [HBsAg] positive and/or detectable HBV DNA) and virus (defined as anti-hepatitis C virus [HCV] Ab positive and detectable HCV ribonucleic acid [RNA] infection or a known history of hepatitis B and/or C infection
  • Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's ability to cooperate with the requirements of the study
  • Has gastrointestinal (GI) obstruction, poor oral intake, or difficulty in taking oral medication
  • Has poorly controlled diarrhea
  • Has had a major surgery or significant traumatic injury within 4 weeks before the first dose of study intervention
  • Has history of allogeneic tissue/solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Pembrolizumab plus Chemotherapy

    Participants will receive pembrolizumab 400 mg via intravenous (IV) injection on day 1 of every 6 week cycle (Q6W) for up to 18 cycles (up to \~2 years) AND investigator's choice of CAPOX chemotherapy (capecitabine 1000 mg/m\^2 orally twice daily for 14 days every 3 weeks (Q3W) and oxaliplatin 130 mg/m\^2 via IV infusion Q3W) OR mFOLFOX6 chemotherapy (oxaliplatin 85 mg/m\^2 via IV infusion Q3W; 5-Fluorouracil (5-FU) 400 mg/\^2 via bolus IV plus 2400 mg/m\^2 continuous IV once every 2 weeks (Q2W); and leucovorin 400 mg/m\^2 via IV infusion Q2W OR levoleucovorin 200 mg/m\^2 Q2W).

    Biological: Pembrolizumab · Drug: Capecitabine · Drug: Leucovorin · Drug: Levoleucovorin · Drug: 5-Fluorouracil (5-FU) · Drug: Oxaliplatin

  • Experimental
    Pembrolizumab plus Sacituzumab Tirumotecan plus Chemotherapy

    Participants will receive sacituzumab tirumotecan via IV infusion on Days 1, 15, and 29 Q6W until discontinuation, pembrolizumab 400 mg via IV injection on day 1 Q6W for up to 18 cycles (up to \~2 years) AND investigator's choice of capecitabine 1000 mg/m\^2 orally twice daily for 14 days Q3W OR 5-FU 2400 mg/m\^2 IV once Q2W AND leucovorin 400 mg/m\^2 via IV infusion Q2W OR levoleucovorin 200 mg/m\^2 Q2W.

    Biological: Pembrolizumab · Biological: Sacituzumab Tirumotecan (sac-TMT) · Drug: Capecitabine · Drug: Leucovorin · Drug: Levoleucovorin · Drug: 5-Fluorouracil (5-FU)

  • Experimental
    Pembrolizumab plus Patritumab Deruxtecan plus Chemotherapy

    Participants will receive patritumab deruxtecan via IV infusion on Days 1 and 22 Q6W until discontinuation, pembrolizumab 400 mg via IV injection on day 1 Q6W for up to 18 cycles (up to \~2 years) AND investigator's choice of capecitabine 1000 mg/m\^2 orally twice daily for 14 days Q3W OR 5-FU 2400 mg/m\^2 IV once Q2W AND leucovorin 400 mg/m\^2 via IV infusion Q2W OR levoleucovorin 200 mg/m\^2 Q2W.

    Biological: Pembrolizumab · Drug: Capecitabine · Drug: Leucovorin · Drug: Levoleucovorin · Drug: 5-Fluorouracil (5-FU) · Biological: Patritumab Deruxtecan

Interventions

  • BiologicalPembrolizumab

    Administered via intravenous (IV) infusion.

    Also known as: MK-3475, Keytruda®

  • Administered via IV infusion.

    Also known as: MK-2870, SKB264

  • Administered via oral tablet.

    Also known as: XELODA

  • Administered via IV infusion.

    Also known as: calcium folinate, folinic acid, WELLCOVORIN®

  • Administered via IV infusion.

    Also known as: calcium levofolinate, levofolinic acid, FUSILEV®

  • Administered via IV infusion

    Also known as: ADRUCIL®

  • Administered via IV infusion

  • Administered via IV infusion

    Also known as: HER3-DXd, MK-1022, U3-1402

06

What researchers measure

Primary outcomes

  1. Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)

    DLTs are defined as any treatment-emergent adverse events (TEAEs) not attributable to disease or disease-related processes that occur during the DLT evaluation period and are a Grade 3 or higher according to the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0. The percentage of participants who experience at least one DLT will be reported.

    Time frame: Up to approximately 28 days

  2. Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 28 days

  3. Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 28 days

  4. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

    ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented.

    Time frame: Up to approximately 28 months

Secondary outcomes

  1. Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

    Time frame: Up to approximately 55 months

  2. Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

    Time frame: Up to approximately 55 months

  3. Overall Survival (OS)

    OS is defined as the time from randomization to the date of death from any cause.

    Time frame: Up to approximately 55 months

  4. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 55 months

  5. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 55 months

  6. Incidence of Antidrug Antibodies (ADA) to investigational agents - (sacituzumab tirumotecan (sac-TMT, MK-2870) and patritumab deruxtecan (HER3-DXd))

    Blood samples collected at designated timepoints will be used to determine the ADA response to investigational agents. The incidence of ADAs over time will be presented.

    Time frame: At designated timepoints up to approximately 55 months

07

Study locations

44 of 50 sites recruiting
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)
    Tucson, Arizona 85719, United States
    Recruiting
    • Study Coordinator · Contact520-621-2449
  • UCLA Hematology/Oncology - Santa Monica ( Site 6905)
    Los Angeles, California 90404, United States
    Recruiting
    • Study Coordinator · Contact310-570-1453
  • Norton Hospital-Norton Cancer Institute - Downtown ( Site 6900)
    Louisville, Kentucky 40202, United States
    Completed

    Not enrolling at this site — choose another above.

  • The Cancer and Hematology Centers ( Site 6912)
    Grand Rapids, Michigan 49503, United States
    Recruiting
    • Study Coordinator · Contact616-975-3065
  • Hematology-Oncology Associates of Central NY, P.C. ( Site 6925)
    East Syracuse, New York 13057, United States
    Recruiting
    • Study Coordinator · Contact315-472-7504
  • Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 6907)
    New York, New York 10032, United States
    Completed

    Not enrolling at this site — choose another above.

  • UPMC Hillman Cancer Center-UPMC ( Site 6904)
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Study Coordinator · Contact816-898-9413
  • University of Texas MD Anderson Cancer Center ( Site 6920)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact833-589-0868
  • Liga Norte Riograndense Contra o Câncer ( Site 6303)
    Natal, Rio Grande do Norte 59062-000, Brazil
    Recruiting
    • Study Coordinator · Contact+558440095595
  • Hospital Nossa Senhora da Conceição ( Site 6301)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
    Recruiting
    • Study Coordinator · Contact+5551993590437
  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 6300)
    São Paulo, 01246-000, Brazil
    Recruiting
    • Study Coordinator · Contact551138932000
  • IBCC - Instituto Brasileiro de Controle do Câncer ( Site 6304)
    São Paulo, 03102-006, Brazil
    Recruiting
    • Study Coordinator · Contact551144500300
  • Clínica Puerto Montt ( Site 6409)
    Port Montt, Los Lagos Region 5500243, Chile
    Recruiting
    • Study Coordinator · Contact56961687093
  • Centro de Investigación del Maule ( Site 6408)
    Talca, Maule Region 3481349, Chile
    Completed

    Not enrolling at this site — choose another above.

  • FALP-UIDO ( Site 6400)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact56224205098
  • Centro de Oncología de Precisión-Oncology ( Site 6404)
    Santiago, Region M. de Santiago 7560908, Chile
    Recruiting
    • Study Coordinator · Contact56225189885
  • Clínica UC San Carlos de Apoquindo ( Site 6405)
    Santiago, Region M. de Santiago 7620002, Chile
    Recruiting
    • Study Coordinator · Contact56934271024
  • Bradfordhill-Clinical Area ( Site 6401)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact56229490970
  • Bradford Hill Norte ( Site 6407)
    Antofagasta, 1263521, Chile
    Recruiting
    • Study Coordinator · Contact56442023631
  • Beijing Cancer hospital-Digestive Oncology ( Site 5500)
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Study Coordinator · Contact(010)88196317
  • The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 5501)
    Fuzhou, Fujian 350025, China
    Recruiting
    • Study Coordinator · Contact0591-22859606
  • The First Affiliated hospital of Xiamen University ( Site 5503)
    Xiamen, Fujian 361003, China
    Recruiting
    • Study Coordinator · Contact0592-2139767
  • Henan Cancer Hospital ( Site 5504)
    Zhengzhou, Henan 450008, China
    Recruiting
    • Study Coordinator · Contact400-0371-818
  • The First Affiliated Hospital of Nanchang University ( Site 5514)
    Nanchang, Jiangxi 330000, China
    Recruiting
    • Study Coordinator · Contact0791-86427234
  • Fudan University Shanghai Cancer Center ( Site 5513)
    Shanghai, Shanghai Municipality 200032, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Xinjiang Medical University Cancer Hospital - Urumqi ( Site 5506)
    Ürümqi, Xinjiang 841100, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 5510)
    Hangzhou, Zhejiang 310016, China
    Recruiting
    • Study Coordinator · Contact0571 8609 0073
  • CHU-BREST Cavale Blanche ( Site 5104)
    Brest, Finistere 29200, France
    Recruiting
    • Study Coordinator · Contact33298223428
  • CIC. ( Site 5100)
    Lille, Nord 59037, France
    Recruiting
    • Study Coordinator · Contact+33320445461
  • Pitie Salpetriere University Hospital-Hepato-Gastro-Enterology ( Site 5102)
    Paris, Île-de-France Region 75013, France
    Recruiting
    • Study Coordinator · Contact+331 42 16 10 41
  • NCT-Department of Medical Oncology ( Site 6809)
    Heidelberg, Baden-Wurttemberg 69120, Germany
    Recruiting
    • Study Coordinator · Contact+49 62215637784
  • HOPE Hamburg/Norddeutsches Studienzentrum fuer Innovative Onkologie ( Site 6807)
    Erdgeschoss, Free and Hanseatic City of Hamburg 22297, Germany
    Recruiting
    • Study Coordinator · Contact+ 4940360352246
  • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 6802)
    Düsseldorf, North Rhine-Westphalia 40225, Germany
    Completed

    Not enrolling at this site — choose another above.

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 5207)
    Meldola, Emilia-Romagna 47014, Italy
    Recruiting
    • Study Coordinator · Contact0543739100
  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 5200)
    Milan, Lombardy 20133, Italy
    Recruiting
    • Study Coordinator · Contact0223903807
  • Azienda Ospedaliero Universitaria Pisana ( Site 5206)
    Pisa, Tuscany 56126, Italy
    Recruiting
    • Study Coordinator · Contact050992454
  • Ospedale San Raffaele-Oncologia Medica ( Site 5202)
    Milan, 20132, Italy
    Recruiting
    • Study Coordinator · Contact+390226437615
  • Oslo universitetssykehus, Radiumhospitalet ( Site 6501)
    Oslo, 0379, Norway
    Recruiting
    • Study Coordinator · Contact4723026600
  • Asan Medical Center-Department of Oncology ( Site 5901)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact+82230103217
  • Samsung Medical Center-Division of Hematology/Oncology ( Site 5900)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact82234101795
  • Hôpitaux Universitaires de Genève (HUG) ( Site 6701)
    Geneva, Canton of Geneva 1211, Switzerland
    Recruiting
    • Study Coordinator · Contact+41 22 372 29 01
  • Kantonsspital Graubünden-Medizin ( Site 6700)
    Chur, Kanton Graubünden 7000, Switzerland
    Recruiting
    • Study Coordinator · Contact+41 81 256 61 11
  • China Medical University Hospital ( Site 6007)
    Taichung, 404, Taiwan
    Recruiting
    • Study Coordinator · Contact886422052121x15057
  • National Cheng Kung University Hospital ( Site 6001)
    Tainan, 704, Taiwan
    Recruiting
    • Study Coordinator · Contact+88662353535x4559
  • National Taiwan University Hospital-Oncology ( Site 6000)
    Taipei, 10048, Taiwan
    Recruiting
    • Study Coordinator · Contact+88623123456x267852
  • Taipei Veterans General Hospital ( Site 6005)
    Taipei, 112, Taiwan
    Recruiting
    • Study Coordinator · Contact+88628717270x131
  • Faculty of Medicine Siriraj Hospital ( Site 6102)
    Bangkoknoi, Bangkok 10700, Thailand
    Recruiting
    • Study Coordinator · Contact+6624194489
  • Chulalongkorn Hospital ( Site 6104)
    Pathumwan, Bangkok 10330, Thailand
    Recruiting
    • Study Coordinator · Contact022564533
  • Ramathibodi Hospital ( Site 6103)
    Ratchathewi, Bangkok 10400, Thailand
    Recruiting
    • Study Coordinator · Contact022011671
  • Songklanagarind hospital ( Site 6101)
    Hat Yai, Changwat Songkhla 90110, Thailand
    Recruiting
    • Study Coordinator · Contact+6674451469
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2029, 59 months after the start.

Of 74 phase 1/2 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 92. This study's planned 59 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Jun 24, 2024
StartActual
Sep 20, 2024
Primary completionEst.
Sep 12, 2029
CompletionEst.
Sep 12, 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (2 now completed, 1 now active, not recruiting)
Show 3 sites
  • Centro de Investigación del Maule ( Site 6408) · Talca, ChileRecruiting→Completed
  • Fudan University Shanghai Cancer Center ( Site 5513) · Shanghai, ChinaRecruiting→Active, not recruiting
  • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 6802) · Düsseldorf, GermanyRecruiting→Completed
across 2 updates, Oct 7, 2026 – Nov 13, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Centro de Investigación del Maule ( Site 6408) · Talca, ChileContact removed •••1241
  • Fudan University Shanghai Cancer Center ( Site 5513) · Shanghai, ChinaContact removed •••5590
  • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 6802) · Düsseldorf, GermanyContact removed •••8751
across 2 updates, Oct 7, 2026 – Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    2 sites changed recruiting status (1 now active, not recruiting, 1 now completed)
    Show 2 sites
    • Fudan University Shanghai Cancer Center ( Site 5513) · Shanghai, ChinaRecruiting→Active, not recruiting
    • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 6802) · Düsseldorf, GermanyRecruiting→Completed
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Fudan University Shanghai Cancer Center ( Site 5513) · Shanghai, ChinaContact removed •••5590
    • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 6802) · Düsseldorf, GermanyContact removed •••8751
    + 1 other change: verification date
  2. Oct 7, 2026
    Centro de Investigación del Maule ( Site 6408) is now Completed
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Centro de Investigación del Maule ( Site 6408) · Talca, ChileContact removed •••1241
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06469944
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Sep 20, 2024
Primary completion
Sep 12, 2029 (estimated)
Completion
Sep 12, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sacituzumab tirumotecan · Patritumab deruxtecan

Start the discussion